BioLineRx Ltd. (BLRX)
Total Valuation
BioLineRx has a market cap or net worth of $82.69 million. The enterprise value is $51.28 million.
Market Cap | 82.69M |
Enterprise Value | 51.28M |
Important Dates
The last earnings date was Tuesday, March 26, 2024, before market open.
Earnings Date | Mar 26, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 78.04 million shares outstanding.
Shares Outstanding | 78.04M |
Owned by Insiders (%) | 9.43% |
Owned by Institutions (%) | 1.67% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 17.23 |
Forward PS | n/a |
PB Ratio | 6.25 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 10.68 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.88.
Current Ratio | 1.53 |
Quick Ratio | 1.43 |
Debt / Equity | 0.88 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -26.95 |
Financial Efficiency
Return on equity (ROE) is -280.20% and return on invested capital (ROIC) is -200.27%.
Return on Equity (ROE) | -280.20% |
Return on Assets (ROA) | -99.20% |
Return on Capital (ROIC) | -200.27% |
Revenue Per Employee | $97,959 |
Profits Per Employee | -$1.24M |
Employee Count | 49 |
Asset Turnover | 0.08 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.23% in the last 52 weeks. The beta is 0.93, so BioLineRx's price volatility has been similar to the market average.
Beta (1Y) | 0.93 |
52-Week Price Change | +30.23% |
50-Day Moving Average | 1.21 |
200-Day Moving Average | 1.51 |
Relative Strength Index (RSI) | 44.55 |
Average Volume (30 Days) | 322,329 |
Short Selling Information
Short Interest | 324,649 |
Short Previous Month | 183,915 |
Short % of Shares Out | 0.45% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.61 |
Income Statement
In the last 12 months, BioLineRx had revenue of $4.80 million and -$60.61 million in losses. Loss per share was -$0.06.
Revenue | 4.80M |
Gross Profit | 1.11M |
Operating Income | -49.69M |
Pretax Income | -60.61M |
Net Income | -60.61M |
EBITDA | -57.06M |
EBIT | -58.45M |
Loss Per Share | -$0.06 |
Balance Sheet
The company has $42.99 million in cash and $11.59 million in debt, giving a net cash position of $31.40 million or $0.40 per share.
Cash & Cash Equivalents | 42.99M |
Total Debt | 11.59M |
Net Cash | 31.40M |
Net Cash Per Share | $0.40 |
Equity / Book Value | 13.22M |
Book Value Per Share | 0.17 |
Working Capital | 16.33M |
Cash Flow
In the last 12 months, operating cash flow was -$22.61 million and capital expenditures -$116,000, giving a free cash flow of -$22.72 million.
Operating Cash Flow | -22.61M |
Capital Expenditures | -116,000 |
Free Cash Flow | -22.72M |
FCF Per Share | -$0.35 |
Margins
Gross margin is 23.08%, with operating and profit margins of -1,035.29% and -1,262.79%.
Gross Margin | 23.08% |
Operating Margin | -1,035.29% |
Pretax Margin | -1,262.79% |
Profit Margin | -1,262.79% |
EBITDA Margin | -1,188.77% |
EBIT Margin | -1,217.60% |
FCF Margin | -473.42% |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -24.47% |
Shareholder Yield | -24.47% |
Earnings Yield | -73.31% |
FCF Yield | -27.48% |
Analyst Forecast
The average price target for BioLineRx is $12.50, which is 1,016.07% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $12.50 |
Price Target Difference | 1,016.07% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on July 15, 2019. It was a reverse split with a ratio of 1:15.
Last Split Date | Jul 15, 2019 |
Split Type | Reverse |
Split Ratio | 1:15 |
Scores
BioLineRx has an Altman Z-Score of -10.21 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -10.21 |
Piotroski F-Score | 2 |